CGEM MEXC RealStocks
Own real CGEM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:26:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cullinan Therapeutics, Inc. (CGEM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $9.01, with a market capitalization of $602.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.23 to $23.19. This page covers its latest market performance, valuation, price trends and company information.
$602.14M | |
$9.24 | |
$9.54 | |
$8.82 | |
$9.28 | |
972.80K | |
993.30K | |
-- | |
$23.19 | |
$8.23 | |
-- | |
2026-09-30 |
Cullinan Therapeutics, Inc. (CGEM) last closed at $9.01 as of 2026-11-19 01:00:00, down 3.02% ($0.28) from the previous close of $9.28.
During the latest regular trading session, CGEM traded between $8.82 and $9.54, with a volume of 972.80K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Cullinan Therapeutics, Inc. (CGEM) moved from $11.23 to $9.01, representing a decline of 19.81% ($2.22).
The stock traded between $8.47 and $12.04 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.12 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.2%
CGEM is currently trading at $9.01, placing it 5.2% of the way from its 52-week low of $8.23 to its 52-week high of $23.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 109 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cullinan Therapeutics, Inc. (CGEM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CGEM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CGEM shares and USD.
CGEM Shares to USD
1.00 CGEM shares = 9.005 USD
Calculations are estimates based on the latest available price and are for reference only.